Concept
Antibody-dependent enhancement
Related people (22)
Didier Trono
After obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.
Bruno Emanuel Ferreira De Sousa Correia
Throughout my PhD and postdoctoral studies I was trained in world-renowned laboratories and institutions in the United States of America (University of Washington and The Scripps Research Institute). Very early in my scientific career I found out my fascination about protein structure and function. My PhD studies evolved in the direction of immunogen design and vaccine engineering which sparked my interest in the many needs and opportunities in vaccinology and translational research. My efforts resulted in an enlightening piece of work where for the first time, computationally designed immunogens elicited potent neutralizing antibodies. During my postdoctoral studies I joined a chemical biology laboratory at the Scripps Research Institute. In this stage I developed novel chemoproteomics methods for the identification of protein-small molecule interaction sites in complex proteomes. In March 2015, I joined the École Polytechnique Fédérale de Lausanne (EPFL) – Switzerland as a tenure track assistant professor. The focus of my research group is to develop computational tools for protein design with particular emphasis in applying these strategies to immunoengineering (e.g. vaccine and cancer immunotherapy). The activities in my laboratory focus on computational design methods development and experimental characterization of the designed proteins. Our laboratory has been awarded with 2 prestigious research grants from the European Research Council. Lastly, I have been awarded the prize for best teacher of Life sciences in 2019.
Priscilla Turelli
Positions
2005-now: Research associate, Federal School of Life Sciences, Laboratory of Virology and Genetics, Lausanne, Switzerland
2001-2004: Research associate in Pr D. Tronos laboratory, Department of Microbiology, Geneva School of Medicine, Switzerland
1997-2001: Post-doctoral research fellow in Pr D. Tronos laboratory, Department of Microbiology, Geneva School of Medicine, Switzerland
Honors and fellowships 2004: Bristol-Myers Squibb AIDS AWARD 1997-1999: Human Frontier Science Program fellowship
Education June 1997: PhD in cellular biology. Final mark:jury congratulations. Université de la Méditerranée, France. June 1993: Post-graduate diploma in cellular biology and microbiology. INSERM U372, Marseille-Luminy, université de Provence, France. June 1992: Master in cellular biology Specialty: genetic. Final mark: Best master student of this year. Université de la Méditerranée, France. June 1987: Scientific baccalaureate, France.
Teaching experience 2009-now: phD thesis co-director, School of Life Sciences, Lausanne, Switzerland. 2002: Tutor in virology for medical students, 2nd year, Geneva School of Medicine, Switzerland. 1996-1997: Tutor in molecular biology and biochemistry for under-graduate students, Université de la Méditerranée, Aix Marseille II, France.
Honors and fellowships 2004: Bristol-Myers Squibb AIDS AWARD 1997-1999: Human Frontier Science Program fellowship
Education June 1997: PhD in cellular biology. Final mark:jury congratulations. Université de la Méditerranée, France. June 1993: Post-graduate diploma in cellular biology and microbiology. INSERM U372, Marseille-Luminy, université de Provence, France. June 1992: Master in cellular biology Specialty: genetic. Final mark: Best master student of this year. Université de la Méditerranée, France. June 1987: Scientific baccalaureate, France.
Teaching experience 2009-now: phD thesis co-director, School of Life Sciences, Lausanne, Switzerland. 2002: Tutor in virology for medical students, 2nd year, Geneva School of Medicine, Switzerland. 1996-1997: Tutor in molecular biology and biochemistry for under-graduate students, Université de la Méditerranée, Aix Marseille II, France.
Michel Aguet
Dr. Michel Aguet, MD, held positions in academia and industry (Associate Professor at the Institute of Molecular Biology, University of Zürich; Head of Molecular Oncology, Genentech, So. San Francisco) before he was appointed director of the Swiss Institute for Experimental Cancer Research (ISREC) (1996-2009). In the context of the integration of ISREC into the Swiss Federal Institute of Technology (EPFL), he was appointed as Full Professor at the newly established School of Life Sciences in 2005. From 2001-2013 he directed the National Center of Competence in Research (NCCR) in Molecular Oncology, a national program launched by the Swiss National Science Foundation to encourage translational cancer research and for which ISREC was the leading house. Dr. Aguet has been a SAB member in the pharmaceutical industry, biotech industry and venture capital industry since 1997.
A large part of his scientific career was devoted to exploring the molecular biology of interferons (cloning of the interferon gamma receptor, generation of various interferon signaling mutants in the mouse) and, in collaboration with Prof. Charles Weissmann, to investigating the role of prion related protein PrP in mouse prion disease models. In recent years his research focused on characterizing the role of BCL9 proteins, which are part of the Wnt/beta-catenin transcriptional activation complex, in regulating stem cell traits in intestinal epithelium and colorectal cancer. His laboratory is now closed due to retirement.
Florian Maria Wurm
Florian Wurm received his academic training as a Biologist and Molecular Geneticist at the University of Giessen. He joined the Hoechst AG (Behringwerke) in Marburg as head of a laboratory in Virology. Working with immortalized mammalian cells for the establishment of production processes for alpha-interferons provided the first opportunity to combine basic research with medical application. In 1984 he joined Harvard Medical School in Boston as a Research Fellow in Molecular Biology. 1986 he took an offer from Genentech Inc. in San Francisco to work in Process Sciences on the development of large scale manufacturing processes for recombinant proteins. There he has held a number of leading positions and has acquired intimate knowledge in the generation of protein pharmaceuticals in mammalian cells in bioreactors (a number of which are now marketed products). In 1995 he joined the EPFL as a Professor for Biotechnology. Wurm has published more than 250 scientific papers and holds more than 20 patents/patent-applications. His H-index stands at 60 in 2021. He was Chairman (2005-2009) and is member of the Executive Board of the European Society of Animal Cell Technology (ESACT). He serves as a consultant to the pharmaceutical Biotech Industry, mainly in the fields of animal cell technology for recombinant protein production and in regulatory affairs. He works as a scientific reviewer and editior/asscciate editor for a number of international journals in the Biotech field. F.M. Wurm teaches classes to pre- and postgraduate students in the fields of Molecular and Cellular Biotechnology.
He was founder and Chief Scientific Officer of ExcellGene SA, a 2001 established company in Monthey, Switzerland. He took the position of President and CEO of ExcellGene in 2015. He retired from the CEO position in 2017 and continues to be President and Chief Scientific Officer of ExcellGene.
In 2008 Dr. Wurm was appointed Visiting Professor for Biotechnology at Jinan University in Guangzhou, China. He retired from his position at the EPFL in 2015. His laboratory is closed. With his team at ExcellGene and in collaboration with Dr. Paco Pino, Director of R&D, he continues to explore manufacturing sciences with animal cells in bioreactors.
Jean-Louis Scartezzini
Director of EPFL Solar Energy and Building Physics Laboratory (1994-present); Founder & Director of ENAC Institute of Infrastructures, Resources and Environment (2002-2009); Founder & Director of EPFL Doctoral Program in Environment (2002-2009); Co-Director of EPFL Institute of Building Technology (1994-1997); Associate Professor of Building Physics at EPFL (1994-1997); Associate Professor of Building Physics at University of Geneva (1990-1997); Group Leader & Research Fellow at the EPFL Solar Energy Research Group (1981-1989); Research Fellow at the Applied Geophysics Institute of University of Lausanne (1980-1981).
Francesco Stellacci
Francesco Stellacci graduated in Materials Engineering at the Politecnico di Milano in 1998 with a thesis on photochromic polymers with Prof. Giuseppe Zerbi and Mariacarla Gallazzi. In 1999 he moved to the Chemistry Department of the University of Arizona for as a post-doc in the group of Joe Perry in close collaboration with the group of Seth Marder. In 2002 he moved to the Department of Materials Science and Engineering at the Massachusetts Institute of Technology as an assistant professor. He was then promoted to associate without (2006) and with tenure (2009). In 2010 he moved to the Institute of Materials at EPFL as a full Professor. He holds the Alcan EP Chair. Francesco was one of the recipients of the Technology Review TR35 "35 Innovator under 35" award in 2005, and the Popular Science Magazine "Brilliant 10" award in 2007. He has been a Packard Fellow starting 2005.